{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:00:24Z","timestamp":1787731224712,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.atherosclerosis.2024.119042","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:48:22Z","timestamp":1730436502000},"page":"119042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The role of maintaining lower LDL-C level during statin treatment for advanced CKD patients"],"prefix":"10.1016","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7293-0149","authenticated-orcid":false,"given":"Chieh-Li","family":"Yen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Chia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ran","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pao-Hsien","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chung","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsiang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119042_bib1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0008-6363(00)00169-3","article-title":"Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation","volume":"48","author":"Babaei","year":"2000","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.119042_bib2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jacl.2018.06.011","article-title":"Twenty-year epidemiologic study on LDL-C levels in relation to the risks of atherosclerotic event, hemorrhagic stroke, and cancer death among young and middle-aged population in China","volume":"12","author":"Zhang","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.119042_bib3","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1161\/STROKEAHA.108.516450","article-title":"Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial","volume":"39","author":"Sillesen","year":"2008","journal-title":"Stroke"},{"issue":"21","key":"10.1016\/j.atherosclerosis.2024.119042_bib4","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.119042_bib5","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jacc.2019.07.037","article-title":"Impact of LDL cholesterol on microvascular versus macrovascular disease: a mendelian randomization study","volume":"74","author":"Emanuelsson","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119042_bib6","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.18632\/aging.102763","article-title":"LDL-C plays a causal role on T2DM: a Mendelian randomization analysis","volume":"12","author":"Pan","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2024.119042_bib7","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMra1806939","article-title":"Lipid management for the prevention of atherosclerotic cardiovascular disease","volume":"381","author":"Michos","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119042_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12010071","article-title":"The role of cumulative LDL cholesterol in cardiovascular disease development in patients with familial hypercholesterolemia","volume":"12","author":"Korneva","year":"2022","journal-title":"J. Personalized Med."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.119042_bib9","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/art.40892","article-title":"A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis","volume":"71","author":"Kitas","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"20","key":"10.1016\/j.atherosclerosis.2024.119042_bib10","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"9435","key":"10.1016\/j.atherosclerosis.2024.119042_bib11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.119042_bib12","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2024.119042_bib13","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1161\/CIRCULATIONAHA.119.044282","article-title":"Secondary prevention for atherosclerotic cardiovascular disease: comparing recent US and European guidelines on dyslipidemia","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.119042_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.23736\/S0392-9590.20.04538-1","article-title":"Cardiovascular disease and stroke risk assessment in patients with chronic kidney disease using integration of estimated glomerular filtration rate, ultrasonic image phenotypes, and artificial intelligence: a narrative review","volume":"40","author":"Jamthikar","year":"2021","journal-title":"Int. Angiol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.119042_bib15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.kint.2016.09.049","article-title":"Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review","volume":"91","author":"Mathew","year":"2017","journal-title":"Kidney Int."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2024.119042_bib16","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","article-title":"Chronic kidney disease and coronary artery disease: JACC state-of-the-art review","volume":"74","author":"Sarnak","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.119042_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/1179546821998347","article-title":"Uraemic cardiomyopathy: a review of current literature","volume":"15","author":"Garikapati","year":"2021","journal-title":"Clin. Med. Insights Cardiol."},{"issue":"9784","key":"10.1016\/j.atherosclerosis.2024.119042_bib18","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119042_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ki.2013.181","article-title":"LDL cholesterol in CKD--to treat or not to treat?","volume":"84","author":"Massy","year":"2013","journal-title":"Kidney Int."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.119042_bib20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/qjmed\/hcx040","article-title":"Meta-analysis of statins in chronic kidney disease: who benefits?","volume":"110","author":"Messow","year":"2017","journal-title":"QJM"},{"issue":"19","key":"10.1016\/j.atherosclerosis.2024.119042_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027516","article-title":"Association of low-density lipoprotein cholesterol levels during statin treatment with cardiovascular and renal outcomes in patients with moderate chronic kidney disease","volume":"11","author":"Yen","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.119042_bib22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/pds.4713","article-title":"The Chang Gung Research Database-A multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan","volume":"28","author":"Shao","year":"2019","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"19","key":"10.1016\/j.atherosclerosis.2024.119042_bib23","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat. Med."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.119042_bib24","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"Kidney disease: improving global outcomes lipid guideline development work group M. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int."},{"issue":"Suppl 2","key":"10.1016\/j.atherosclerosis.2024.119042_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr. Pract."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119042_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.119042_bib27","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.119042_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100624","article-title":"All-cause and cardiovascular-related mortality in CKD patients with and without heart failure: a population-based cohort study in kaiser permanente southern California","volume":"5","author":"Yu","year":"2023","journal-title":"Kidney Med"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119042_bib29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1681\/ASN.2014030253","article-title":"ESRD and death after heart failure in CKD","volume":"26","author":"Sud","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.119042_bib30","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3390\/ijerph8051631","article-title":"Protein-energy wasting and mortality in chronic kidney disease","volume":"8","author":"Bonanni","year":"2011","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"2019","key":"10.1016\/j.atherosclerosis.2024.119042_bib31","first-page":"140","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","year":"2019","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.119042_bib32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/0003319718780041","article-title":"Association of dyslipidemia, oxidative stress, and inflammation with redox status in VLDL, LDL, and HDL lipoproteins in patients with renal disease","volume":"69","author":"Miljkovic","year":"2018","journal-title":"Angiology"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.119042_bib33","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/HJH.0b013e32831997d6","article-title":"Statin treatment reduces glomerular inflammation and podocyte damage in rat deoxycorticosterone-acetate-salt hypertension","volume":"27","author":"Hartner","year":"2009","journal-title":"J. Hypertens."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.119042_bib34","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ki.2008.231","article-title":"Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease","volume":"74","author":"Fried","year":"2008","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.119042_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119042_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1910355","article-title":"A comparison of two LDL cholesterol targets after ischemic stroke","volume":"382","author":"Amarenco","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.119042_bib37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ene.12273","article-title":"Association between statin use and intracerebral hemorrhage: a systematic review and meta-analysis","volume":"21","author":"Lei","year":"2014","journal-title":"Eur. J. Neurol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024012140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024012140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T15:20:17Z","timestamp":1732807217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024012140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":37,"alternative-id":["S0021915024012140"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.119042","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of maintaining lower LDL-C level during statin treatment for advanced CKD patients","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.119042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119042"}}